Eliminating the label exclusion enables clinicians to consider axi-cel for relapsed/refractory primary CNS lymphoma, despite the disease not being explicitly added as an indicated population. Phase 1 ...

Libtayo showed similar SPT rates to placebo but improved DFS in high-risk CSCC patients post-surgery and radiotherapy. The C-POST trial demonstrated Libtayo's superior DFS rates, with 81.1% at 24 ...

As survival rates for female-specific cancers continue to rise, therapy-related myeloid neoplasms (t-MN) have become a ...

Advanced Health & Education, a Joint Commission-accredited treatment center in Eatontown, New Jersey, addresses widespread ...